anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Quote

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 18,554
Current window 15,001-15,030
Pages 619
Rows per page 30
Component: Quoteclear collectionreset all
18 30 60

Component

15,001-15,030 of 18,554

filter-aware
201
The slide presents a patient-reported adverse event (FAERS) to challenge the safety profile of a pharmaceutical product.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
202
The slide explicitly frames the narrative as a potential cover-up, contrasting patient statements with official physician office clarifications.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
205
The slide presents a qualitative case study (anecdotal evidence) regarding a potential adverse drug event.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
206
The slide highlights specific clinical symptoms and diagnostic procedures (EKG, cardiac enzymes, telemetry) used to rule out cardiac issues.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
207
The slide uses a Q&A format to document a specific interaction between a doctor and a pharmaceutical sales representative.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
209
The slide uses a table to contrast the clinical trial design with the author's thesis that the evidence standard is too low.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
211
The slide uses a table from a Lancet paper to argue that pitolisant's performance was inferior to modafinil, contradicting the company's narrative.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
214
The slide uses excerpts from French regulatory documents to prove the existence and negative results of the unpublished HARMONY 4 trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
217
The slide uses a screenshot of the ESS website to undermine the credibility of the clinical trial endpoint.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
219
The slide uses a 'villain' framing for the Epworth Sleepiness Scale to justify why it should not be used in the context of the research.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
220
The slide uses a critical tone to re-evaluate clinical trial data, highlighting the gap between statistical results and clinical meaningfulness.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
228
The slide highlights a recurring methodological inconsistency across multiple clinical trials, suggesting regulatory oversight failure.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
229
The slide highlights a specific regulatory failure/contradiction regarding the acceptance of post-hoc analysis in clinical trials.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
230
The slide uses a redacted document image to illustrate the lack of transparency in the FDA's review process compared to the EMA's.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
231
The slide uses a 'villain' framing for the FDA reviewer's oversight.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
232
The slide highlights a discrepancy between raw ESS scores and adjusted LS means, accusing the sponsor of data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
234
The slide details three specific statistical and methodological reasons for the FDA's rejection of the HARMONY 1 study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
235
The slide uses a strong, accusatory tone ('sycophancy', 'red flags') to frame the FDA's regulatory process as flawed.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
237
The slide uses a 'villain' framing to discredit the reliability of clinical data originating from Russia and Eastern Europe.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
239
The slide highlights the ambiguity in the definition of 'cataplexy' used in the study protocol, leading to potential data reliability issues.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
241
The slide uses red text for emphasis on specific criticisms (dose response, centre effect).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
242
The slide uses a CONSORT-style flow diagram to illustrate patient attrition in a clinical trial.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
245
The slide uses red text and boxes to emphasize the contradiction between the trial paper's claims and the EMA's findings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
247
The slide serves as a qualitative research summary based on 16 expert interviews.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
249
The slide presents qualitative interview summaries as evidence of poor market reception.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
250
The slide presents anecdotal evidence from four specific prescribers, highlighting skepticism, reimbursement hurdles, and varying levels of adoption.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
251
The slide presents qualitative interview summaries highlighting drug discontinuation, safety concerns, and competitive disadvantages.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
252
The slide presents qualitative interview data from four distinct medical professionals, highlighting skepticism, lack of efficacy, and safety concerns.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
255
The slide uses a Q&A format to present qualitative feedback from a medical expert.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
256
The slide uses direct quotes from a physician to highlight low adoption and skepticism.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit